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Role of elevated lecithin: Cholesterol acyltransferase and cholesteryl
ester transfer protein activities in abnormal lipoproteins from proteinuric
patients. Lecithin:cholesterol acyltransferase (LCAT) and cholesteryl
ester transfer protein (CETP) are key factors in the esterification of free
cholesterol, and the distribution of cholesteryl ester among lipoproteins
in plasma. Alterations in these processes may play a role in the
lipoprotein abnormalities associated with glomerular proteinuria. The
activities of LCAT and CETP were measured using excess exogenous
substrate assays in nine patients with nephrotic-range proteinuria and in
18 matched controls. The proteinuria-lowering effect of four weeks of
angiotensin converting enzyme (ACE) inhibition with enalapril was also
studied. Plasma very low lipoprotein and low density lipoprotein
(VLDL and LDL) cholesterol, triacyiglycerol and apolipoprotein B
levels were significantly elevated in the patients compared with con-
trols. High density lipoprotein (HDL) total cholesterol, free cholesterol,
cholesteryl ester and the free cholesterol/cholesteryl ester ratio in HDL
were lower. Total plasma apolipoprotein A1 was normal. Plasma LCAT
and CETP activities were elevated in the patients by 30% (P < 0.01) and
by 39% (P < 0.01), respectively, and were both inversely related to
serum albumin. VLDL and LDL cholesterol levels were positively
related to LCAT and CETP activities, whereas the HDL free choles-
terol content was inversely related to LCAT activity. ACE inhibition
resulted in a 40% reduction of proteinuria, a partial normalization of
LCAT activity, and a decrease in VLDL and LDL cholesterol. In
conclusion, elevated activities of LCAT and CETP may provide a
mechanism that contributes to the low proportion of cholesterol in HDL
relative to that in VLDL and LDL, as well as to the compositional
changes of HDL seen in glomerular proteinuria. Such abnormalities
could contribute to accelerated development of atherosclerosis in
proteinuric states.
Hyperlipidemia is a well recognized feature of the nephrotic
syndrome [1—5]. Increased hepatic lipoprotein production and
defective catabolism have been implicated in the abnormal lipid
levels associated with glomerular proteinuria [5]. It is assumed
that the hepatic synthesis of cholesterol and triacyiglycerol in
low and very low density lipoproteins (LDL and VLDL) is
increased in response to hypoalbuminemia, low plasma oncotic
pressure and renal protein leakage [2, 5—7]. High density
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lipoprotein (HDL) cholesterol levels have been reported to be
low [1, 3], normal [2, 8, 9], or even elevated [4].
Among other pathways, the processes of cholesteryl ester
formation and transfer are of great importance in the intravas-
cular metabolism of lipoproteins [10—12]. A major proportion of
cholesteryl ester in plasma is generated through the esterifica-
tion of free cholesterol by the action of lecithin:cholesterol
acyltransferase (LCAT), HDL being the preferred substrate for
the LCAT reaction [103. Subsequently, cholesteryl ester is
transferred toward apolipoprotein B-containing lipoproteins by
the action of cholesteryl ester transfer protein (CETP) [11, 121.
Little information is available on the possible alterations in
plasma LCAT and CETP in relation to glomerular proteinuria.
In the nephrotic syndrome the plasma cholesterol esterification
rate by LCAT was found to be reduced or normal, depending on
the method used [13, 14]. Plasma CETP activity is elevated in
hypercholesterolemia, dysbetalipoproteinemia and type 1 (in-
sulin-dependent) diabetes mellitus, particularly in conjunction
with microalbuminuria and cardiovascular disease [15—18].
We hypothesized that abnormal activities of LCAT and
CETP might provide a mechanism that contributes to the
altered lipoproteins associated with proteinuria. In the present
study we measured plasma LCAT and CETP using exogenous
substrate assays that reflect the activities of the enzyme and
transfer protein as such, and related these factors to the
lipoprotein abnormalities in patients with glomerular protein-
uria. Since angiotensin converting enzyme (ACE) inhibitors are
well able to lower urinary protein excretion [19], the effect of
such treatment on the plasma activities of LCAT and CETP was
also studied.
Methods
Subjects
All subjects consented to the procedure which was approved
by the local medical ethics committee. Nine patients with
biopsy proven glomerulopathy and nephrotic-range proteinuria
in excess of 2.5 g124 hr participated in the study (Table 1). Renal
biopsy showed glomeruloscierosis in five and membranous
glomerulopathy in four patients. None of the patients had
severe renal insufficiency, severe hypertension, underlying
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Table 1. Clinical characteristics of proteinuric patients and control subjects
Histological
diagnosis
Age
years Sex
BMI
kg/rn2
Serum creatinine
jsrnol/liter
DBP
mm Hg
Proteinuria
g/24 hr
MGP 37 M 25.0 79 90 7.2
FSGS 38 F 30.5 72 75 6.9
MGP 28 M 24.0 76 60 7.0
FSGS 31 M 23.9 80 75 16.5
MGP 53 M 29.8 90 85 3.4
FSGS 23 F 23.8 134 85 5.1
FSGS 59 M 25.5 194 100 6.2
FSGS 29 M 28.7 85 85 8.7
MGP 26 M 21.9 72 65 2.8
Proteinuric patients 36 12 F:2; M:7 25.9 3.0 98 41 80 13 7.1 4.0(N = 9)
Control subjects 36 12 F:4; M:14 23.4 2.0 92 14 79 9 —(N = 18)
Abbreviations are: MGP, membranous glomerulopathy; F, female; M, male; FSGS, focal segmental glomerulosclerosis; BMI, body mass index;
and DBP, diastolic blood pressure.
systemic disease, diabetes mellitus or thyroid dysfunction.
Each of the nine patients was individually matched with two
healthy controls with respect to age, sex and, if applicable, oral
contraceptive use. The subjects did not use any medication
except oral contraceptives in one female participant. None of
the participants smoked cigarettes and there was no history of
familial hyperlipidemia. Their clinical characteristics are given
in Table 1.
Clinical procedures
Venous blood for the determination of lipids, LCAT and
CETP activities, as well as protein and albumin was obtained
from each subject after a 12 hour fast. The proteinuric patients
were studied firstly at baseline during which no medication was
taken, secondly after four weeks of treatment with the ACE
inhibitor enalapril, in a doses of 10 mg once daily, and thirdly
four weeks after cessation of enalapril therapy (recovery).
Blood pressure and proteinuria (mean of two 24-hr urine
collections) were determined at the end of each period. None of
the patients had edema. A sodium restricted diet of 50 mmol
daily was prescribed throughout the study to enhance the
antiproteinuric effect of ACE inhibition therapy [19]. Blood
pressure was measured with an automated device (Dinamapa)
in the proteinuric patients and with a sphygmomanometer in the
controls. Mean arterial pressure (MAP) was calculated as ¾ x
diastolic pressure + '/ x systolic pressure.
Laboratory measurements
Venous blood was collected into tubes containing 1.5 mg/mI
EDTA as anticoagulant and placed on ice immediately. Eryth-
rocytes were removed within 30 minutes by centrifugation at
3000 rpm for 15 minutes at 4°C. Plasma samples were frozen at
—20°C until assay.
LCAT and CETP activity assays
The plasma level of active LCAT was determined using
excess exogenous substrate containing [3H}-cholesterol as pre-
viously described [20]. Samples were incubated for six hours at
37°C in a total volume of 0.145 ml. The reaction was stopped by
the addition of 0.30 ml cold methanol. The lipids were extracted
twice with 0.4 ml hexane. Free and esterified cholesterol were
separated using disposable silica columns and [3H]-cholesteryl
ester was eluted with 3.0 ml hexane:diethylether (6:1, vol/vol)
[21]. The measured LCAT activities were linear with the
amount of plasma in the incubations.
CETP activity was measured in the supernatant fraction of
each plasma after precipitation of endogenous apolipoprotein
B-containing lipoproteins with sodium phosphotungstate and
MgCl2, according to a previously described procedure [22]. The
isotope assay detects the transfer/exchange of radioactive cho-
lesteryl ester between excess exogenous [l-14C oleate]-cho-
lesteryl ester labeled LDL and excess unlabeled pooled normal
HDL. LCAT was inhibited with dithiobis 2-nitrobenzoic acid.
Incubations were carried out for 16 hours at 37°C. The tubes
were cooled to 4°C to stop the reaction, followed by precipita-
tion of LDL with Mn2 ions. CETP activity was calculated as
the bidirectional transfer of cholesteryl ester between radiola-
beled LDL and unlabeled HDL [23].
The LCAT and CETP activity assays were performed in
duplicate. The within-day coefficients of variation were 4.5%
and 2.7% for LCAT and CETP, respectively. Both LCAT and
CETP activities were related to the LCAT and CETP activities
measured in human pool plasma that was included in each run.
LCAT activity is expressed in nmol esterified cholesterollmllhr
and CETP activity is expressed in nmol cholesteryl ester
transfer/ml/hr. It should be noted that the measured activities of
LCAT and CETP reflect the activities of these factors as such,
and are independent of the endogenous lipoproteins present in
each plasma.
Lipid and apolipoprotein assays
Lipids were measured in whole plasma and in the HDL-
containing supernatant fraction after precipitation of apoli-
poprotein B-containing lipoproteins with polyethylene glycol-
6000 [24]. VLDL + LDL lipids were calculated as the
difference between plasma and the HDL-containing superna-
tant fraction. Total cholesterol was measured by gas chroma-
tography [251, and free cholesterol by a modification of this
method in which the hydrolysis step was omitted. Cholesteryl
ester was calculated by subtracting free cholesterol from total
cholesterol. Triacyiglycerol was measured enzymatically [26].
Phospholipids were measured according to Zilversmit [27].
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Table 2. Serum protein, albumin, and plasma lipids and apolipoproteins
Control subjects
Proteinuric patients (N = 9)
ACE(N = 18) Baseline inhibition Recovery
Serum protein gllirer 70.7 4.2 55.4 6.6' 57.1 72c.d 56.7 8.lC
Serum albumin glliter 48.9 2.9 34.7 49C 35.2 47C 35.6 6.5C
Plasma total cholesterol mmol/liter 5.20 1.01 6.90 1.28" 6.52 1.34"" 7.46 194b
Plasma triacylglycerol mmol/liter 1.31 0.50 2.32 0.91a 2.19 0.83a 2.27 I.o2
HDL cholesterol mmol/liter 1.21 0.17 0.88 0.12" 0.85 0.16" 0.90 0.15"
VLDL + LDL cholesterol mmol/liter 3.99 0.96 6.02 1.33" 5.67 1.38"" 6.56 1.92"
Apolipoprotein A, gluier 1.54 0.13 1.67 0.33 1.65 0.25 1.69 0.29
Apolipoprotein B gluier 0.78 0.17 1.04 0.18" 0.97 0.l5a 1.08 0.23"
Data are mean SD.
a P < 0.05; b D 0.01; P < 0.001 from controls
P < 0.05 from baseline and recovery
Table 3. High density lipoprotein lipids
Control subjects(N = 18) Baseline
Proteinuric patients (N = 9)
ACE inhibition Recovery
Cholesterytestermmol/liter 0.97 0.14 0.74 0.09"
Free cholesterol mmol/liter 0.24 0.07 0.14 0.05"
0.72 0.12"
0.13 0.04"
0.76 0.11"
0.14 0.04"
Cholesterylester mol% 36.14 2.91 34.41 3.70
Free cholesterol mol% 8.87 2.23 6.51 1.39"
35.37 2.90
6.35 1.23"
34.98 3.77
6.28 1.23"
Triacylglycerol mol% 10.19 2.13 11.36 3.73 11.39 3.01 9.66 1.63
Phospholipids mol% 44.80 3.87 47.72 4.34 46.89 3.92 49.08 4.02
Free cholesterol/cholesterylester inoIlmol 0.25 0.07 0.19 0.05" 0.18 O.O4 0.18 0.o4
Cholesterylesterfapolipoprotein A, mmol/g 0.63 0.06 0.45 0.08C 0.44 0.06C 0.46 0.07'
Data are mean SD. Apolipoprotein A1 was determined in total plasma.
a p < 0.05 from controls
b P < 0.01 from controls
C P < 0.001 from controls
Apolipoproteins A1 and B were determined by immunotur-
bidimetry using commercially available kits (Boehringer Mann-
heim, Germany, cat no 726478 and 726494, respectively).
Other techniques
Serum creatinine, total protein and albumin were measured
on a SMA-C autoanalyzer (Technicon Instruments Inc., Tarry-
town, New York, USA). Urinary protein was determined by
the pyrogallol-red-molybdate method [28].
Statistical analysis
Results are expressed as mean SD. Data in the proteinuric
patients were compared to those in the control subjects using
analysis of variance. Adjustment for multiple comparisons was
carried out using Duncan's method. Student's t-tests for paired
observations were used to analyze changes within the proteinu-
nc group. The baseline and recovery data were averaged for
comparison with the data obtained during ACE inhibition to
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Fig. 1. Plasma LCAT activity (A) and CETP
activity (B) in control (•) subjects (N = 18)
and proteinuric patients (D) (N = 9) without
(baseline and recovery) and during
antiproteinuric treatment with an ACE
inhibitor. *D < 0.05; fP  0.01 vs. control
subjects; 1P < 0.05 from baseline and
recovery.
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A the patients (Table 2). In contrast, HDL cholesterol was lower,
whereas total plasma apolipoprotein A1 levels were comparable
in patients and controls. Pronounced alterations were observed
with respect to HDL lipid constituents (Table 3). HDL cho-
o lesteryl ester was decreased in the patients, also when ex-
pressed per amount of total plasma apolipoprotein A1, indicat-
0 ing that cholesteryl ester was depleted in HDL particles. HDL
free cholesterol was profoundly reduced. As a consequence,
the ratio of free cholesterollcholesteryl ester and the free
cholesterol content in HDL (expressed as mol % of total lipids)
was lower. Minor differences in HDL triacylglycerol and phos-
pholipids were present. As shown in Figure 1, plasma LCAT
and CETP activities were elevated in the untreated patients by
30% (54.0 6.8 vs. 41.5 5.8 nmol esterified cholesterollml/hr,
P < 0.01) and by 39% (168.9 37.3 vs. 121.5 33.3 nmol
cholesteryl ester transfer/mLlhr, P < 0.01), respectively. In the
patient group VLDL + LDL cholesterol and apolipoprotein B
20 30 40 50 60 levels were positively related to urinary protein excretion (3
datasets; averaged r = 0.59, P < 0.01 and r = 0.69, P < 0.001,
respectively) and inversely related to serum albumin (averaged
r =
—0.43, P = 0.05 and r = —0.44, P <0.05, respectively).
814 LCAT activity (averaged r =
—0.48, P < 0.03, Fig. 2A) as well
as CETP activity (averaged r =
—0.55, P < 0.01, Fig. 2B) were
also inversely related to serum albumin, but not significantly to
D • urinary protein excretion (averaged r 0.25 and r = 0.24,
0 respectively). These relationships indicated that the lower
0 serum albumin, the more plasma LCAT and CETP activities
0 0 U were increased. LCAT and CETP activities were interrelated in
the patients (averaged r = 0.64, P < 0.01), but not in the control
o subjects. Furthermore, VLDL + LDL cholesterol levels were
• . positively correlated with LCAT as well as CETP activityg
• (averaged r = 0.43, P 0.05, Fig. 3A and r = 0.42, P < 0.06,
Fig. 3B, respectively). In contrast, an inverse correlation was
found between LCAT activity and the HDL free cholesterol
content (averaged r =
—0.59, P < 0.01, Fig. 3C).
During ACE inhibition proteinuria was reduced to 4.2 2.6
I I g/24 hr, as compared with a mean value of 7.1 4.0 g124 hr at
20 30 40 50 60 baseline and of 6.6 3.4 g/hr at recovery (P < 0.01). This 40%
decrease in proteinuria was accompanied by a small increase in
serum protein, whereas serum albumin did not change signifi-
cantly (Table 2). MAP had fallen to 86 10 mm Hg, as
compared with 98 13 mm Hg at baseline and 96 10 mm Hg
at recovery (P < 0.01). ACE inhibition reduced plasma total
cholesterol which was due to a decrease in VLDL + LDL
cholesterol (Table 2). In these lipoproteins cholesteryl ester
decreased to 3.94 0.89 mmol/liter, as compared with 4.29
0.87 mmol/liter at baseline and 4.54 1.09 mmollliter at
recovery (P < 0.05). No significant changes were observed in
HDL lipids (Table 3). ACE inhibition partially normalized
LCAT activity, whereas CETP activity remained unchanged
(Fig. 1). These changes in LCAT activity were positively
correlated with the changes in proteinuria (2 datasets; averaged
r = 0.69, P < 0.01, Fig. 4). The ACE inhibition-induced
reduction in VLDL + LDL cholesterol was related to the
decrease in LCAT activity (averaged r = 0.50, P < 0.06).
Serum albumin, glilter
Fig. 2. Relationships of plasma LCAT activity (A) and CETP activity
(B) with serum albumin. Symbols are: (U) control subjects (N = 18);
(EJ) proteinuric patients (N = 9) at baseline and recovery; (A) proteinu-
nc patients during ACE inhibition. A. LCAT activity and serum
albumin: control subjects r =
—0.16, NS; proteinuric patients (3
datasets) averaged r =
—0.48, P < 0.03. B. CETP activity and serum
albumin: control subjects r =
—0.32, NS; proteinuric patients (3
datasets) averaged r =
—0.55, P < 0.01.
account for possible changes in disease activity over time.
Correlation coefficients were analyzed using linear regression
analysis. Because the proteinuric patients were studied on three
occasions, averaged correlation coefficients were computed by
Z-transformation. A two-sided P-value less than 0.05 was
considered to be significant.
Results
Serum protein and albumin concentrations were lower in the
untreated proteinuric patients than in the control subjects
(Table 2). Plasma total cholesterol, triacylglycerol, VLDL +
LDL cholesterol and apolipoprotein B levels were elevated in
Discussion
This study shows that an abnormal lipoprotein profile is
related to elevated activities of LCAT and CETP in untreated
proteinuric patients. LCAT and CETP activities were inversely
correlated with serum albumin, and the activity of LCAT
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12 A decreased concomitantly with a fall in proteinuria during ACE
inhibition therapy. These findings suggest that increased activ-
ities of LCAT and CETP may play an important role in the
o 10 lipoprotein abnormalities in glomerular proteinuria.
E o It is important to note that the esterification of free choles-
terol by LCAT, and the subsequent distribution of cholesteryl
8 ester among lipoproteins by CETP is not only dependent on the0 activities of the enzyme and transfer protein as such, but also
2 on the composition and concentration of the endogenous li-o 6 poproteins involved [12, 16, 29]. In the present study excess
9 . exogenous substrate assays were used to determine the activi-
+ ties of LCAT and CETP [20, 22]. The assays reflect the
activities of plasma LCAT and CETP as such, and are indepen-
. ,i • dent of endogenous lipoproteins. The increase in plasma LCAT
• level reported here is in apparent contradiction with other
2 observations that used endogenous substrate methods and
30 40 50 60 70 o showed reduced (fractional) cholesterol esterification rates in
LCAT activity nephrotic patients [13, 14]. However, using an exogenous
nmolesterified cholesterol/mi plasma/hr substrate assay instead, normal fractional cholesterol esterifi-
12 cation rates were observed in the same patients [13]. Given theB increase in total plasma free cholesterol in nephrosis, a normal
or reduced fractional esterification rate may even imply an
10 o elevated absolute cholesterol esterification rate [301. Accord-
ingly, elevated levels of LCAT activity and increased absolute0 cholesterol esterification rates, but reduced fractional esterifi-
5 8 o cation rates were recently demonstrated in hypercholester-
0 olemic analbuminemic rats [31]. The increase in CETP activity
ci in proteinuria-related hyperlipidemia is in agreement with pre-
6 •
0
vious findings in primary and secondary hyperlipidemia [15—181.
Preliminary data suggest that the transfer of radiolabeled cho-
o o lesteryl ester between HDL and endogenous apolipoproteinJ 4 • •• B-containing lipoproteins is also increased in nephrotic patients9 . [32]. In how far this increase in CETP activity in glomerular> . U proteinuria enhances cholesteryl ester mass transfer from HDL
2 toward VLDL and LDL apolipoprotein-B containing lipopro-
teins requires further study.
75 100 125 150 175 200 225 250 In the proteinuric patients VLDL and LDL cholesterol levels
CETP activity were positively correlated with urinary protein excretion and
nmoi cholesteryl ester transfer/mi plasma/hr inversely correlated with serum albumin concentration [1, 4, 6,
16 • 7]. Moreover, VLDL and LDL cholesterol levels were posi-
tively related to LCAT as well as CETP activity. These
14 associations would either suggest a shared regulatory distur-bance or a causal relation between plasma LCAT, CETP and
• elevated levels of VLDL and LDL cholesterol. In agreement12 with several other studies, HDL cholesterol was low in the
proteinuric patients [1, 3]. A reduction in the HDL2, the less
•
dense subfraction of HDL, has been consistently found [8, 9].
We measured total HDL and report a decrease in free choles-
2 8 • • • terol, cholesteryl ester and in the free cholesterol/cholesteryl
6 D°
_______________________
—j 0
Fig. 3. Relationships of VLDL + LDL cholesterol with LCAT activity
4 (A) and with CETP activity (B), and of HDL free cholesterol with LCAT
activity (C). Symbols are: (U) control subjects (N = 18); (0) proteinuric
patients (N = 9) at baseline and recovery; (A) proteinuric patients
2 during ACE inhibition. A. VLDL ÷ LDL cholesterol and LCAT
I I I I activity: control subjects r = 0.30, NS; proteinuric patients (3 datasets)
30 40 50 60 70 80 averaged r = 0.43, P = 0.05. B. VLDL + LDL cholesterol and CETP
activity: control subjects r = 0.01, NS; proteinuric patients (3 datasets)
LCAT activity averaged r = 0.42, P < 0.06. C. HDL free cholesterol (in mol% of total
nmoiesterifled cholesterol/mi plasma/hr lipids) and LCAT activity: control subjects r = —0.04, NS; proteinuricpatients (3 datasets) averaged r = —0.59, P < 0.01.
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Change in proteinuria, g/24 hr
Fig. 4. Relationship between ACE inhibition-induced changes in pro-
teinuria and changes in LCAT activity. Proteinuric patients (LI, 2
datasets) averaged r = 0.69, P < 0.01.
ester ratio, but normal plasma apolipoprotein A1 concentra-
tions. These findings indicate a depletion of cholesteryl ester in
HDL particles and support that HDL2 was reduced, since the
free cholesterollcholesteryl ester ratio is higher in HDL2 than in
HDL3 [10]. The reduced HDL free cholesterol content and its
inverse relation with LCAT activity suggests that elevated
levels of LCAT activity provide a mechanism that is implicated
in the proteinuria-related alterations in HDL. However, it is
also possible that an abnormal composition of the LCAT
substrate might modify the cholesterol esterification rate in
vivo. Obviously, the observed HDL cholesteryl ester depletion
cannot be explained by an increase in LCAT activity per Se. It
is plausible that the increase in CETP activity may contribute to
these low HDL cholesteryl ester concentrations. Several lines
of evidence indicate a major role of CETP in HDL metabolism.
Intravenous injection of human CETP into rats causes a de-
crease in HDL, and transgenic mice synthesizing human CETP
have reduced HDL cholesterol levels [33, 34]. Conversely,
immunological inhibition of CETP activity in vivo results in an
increase in HDL cholesteryl ester and HDL particle size [35,
36], whereas HDL cholesterol levels are extremely elevated in
human cases of CETP deficiency [37]. Interestingly, changes in
HDL opposite to those presently observed have been demon-
strated in hypothyroidism [38]. In this situation low LCAT [39]
and CETP activities are likely to be involved in the high ratio of
free cholesterol/cholesteryl ester and the elevated levels of
cholesteryl ester in the HDL fraction [38].
The mechanisms responsible for the increased activities of
LCAT and CETP in conjunction with proteinuria are not
precisely understood. Both activities are a function of their
mass concentration in plasma [17, 40]. Recent data indeed
suggest that CETP mass is elevated in nephrotic patients [41].
LCAT is synthesized by the liver [42]. CETP may be synthe-
sized by the liver as well, but it is uncertain which cell type
contributes most to CETP present in plasma, because CETP
messenger-RNA has also been isolated from a variety of other
cells and tissues [42—44]. In the current study LCAT and CETP
activities were interrelated in the patients, but not in the control
a subjects. In view of a generalized increase in hepatic lipoprotein
synthesis in nephrotic patients [2, 5—7], these findings raise the
possibility of a coordinate increase in the synthesis of these
factors. In this respect it is noteworthy that the concomitant
hypercholesterolemia is not related to increased hepatic albu-
min synthesis, but instead to renal albumin clearance [7]. In the
presently studied patients the activities of LCAT and CETP
were only correlated with serum albumin and not with urinary
protein excretion. Thus, it is uncertain whether the elevated
levels of LCAT and CETP and associated with urinary protein
loss, or with enhanced hepatic albumin synthesis. Recent
experiments have shown increased CETP messenger-RNA
levels in hamster and monkey tissues after cholesterol feeding,
in parallel with elevated LDL cholesterol levels [43, 44].
Therefore, it is possible that high levels of apolipoprotein
B-containing lipoproteins trigger CETP and LCAT synthesis.
Alternatively, we cannot exclude that the catabolism of LCAT
and CETP was impaired, nor that the increase in CETP activity
could have been caused by a decrease in putative inhibitor
activity [45].
During ACE inhibition therapy VLDL and LDL cholesterol
levels were reduced as a result of a decrease in cholesteryl ester
in these lipoproteins. Furthermore, the reduction in VLDL and
LDL cholesterol was related to a decrease in LCAT activity,
suggesting a role of this enzyme in the proteinuria-related
lipoprotein changes. The short period of ACE inhibition could
possibly explain why LCAT activity was only partially normal-
ized and CETP activity remained unchanged. The relationship
between the fall in proteinuria and the decrease in LCAT
activity suggests that more rigorous antiproteinuric treatment
might have induced more pronounced effects.
In conclusion, elevated plasma activities of LCAT and CETP
may provide a mechanism that contributes to the low propor-
tion of HDL relative to that in VLDL and LDL and to the
compositional changes in HDL observed in glomerular protein-
uria. Such abnormalities could contribute to accelerated devel-
opment of atherosclerosis in proteinuric states.
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